SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) and VisionRenu Biomedical Technology Co., Ltd. today announced the signing of a Strategic Memorandum of Understanding (MOU) to collaborate in AI-powered biotechnology, precision medicine, and international capital market initiatives. The agreement, which establishes a framework for cooperation, aims to accelerate VisionRenu's global expansion while creating long-term value through strategic financing, business development, and potential U.S. capital market opportunities.
Under the MOU, SUIC and VisionRenu will combine their respective strengths in medical technology innovation, commercialization, international business development, and access to U.S. capital markets. Both companies view the agreement as the first step toward building a long-term strategic partnership focused on innovation and sustainable growth. The collaboration is intended to position both companies to participate in one of the world's fastest-growing technology sectors.
Artificial Intelligence is rapidly reshaping the biotechnology industry by accelerating advances in gene editing, DNA synthesis, precision medicine, and digital biology. AI enables faster discovery of disease-related genes, improves CRISPR gene-editing precision, optimizes DNA and protein design, and significantly shortens the development cycle for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through the Design-Build-Test-Learn (DBTL) platform, creating a new era of intelligent life science innovation.
Industry analysts expect AI-enabled biotechnology to become one of the world's largest innovation markets over the coming decades, creating multi-trillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials. Aligned with this global trend, SUIC's strategic collaboration and proposed merger with VisionRenu, together with partnerships involving AI biotechnology startups supported by Taiwan's Ministry of Health and Welfare (MOHW), position the Company to expand into this rapidly growing sector.
By leveraging AI, precision medicine, gene technologies, and international capital market resources, SUIC aims to accelerate innovation while building long-term shareholder value. VisionRenu, a Taiwan-based medical technology company specializing in brain health and ophthalmic medical devices, brings its flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, approved by Taiwan's TFDA for the treatment of depression, as well as proprietary ophthalmic laser technologies.
For more information about VisionRenu, visit https://www.vision-renu.com/. To learn more about SUIC, visit https://sinounitedco.com/.
This press release contains forward-looking statements that involve risks and uncertainties. The Framework Agreement announced herein is non-binding, and there can be no assurance that any definitive transaction will be completed.
